Arguments for a different regulatory categorization and framework for stromal vascular fraction.
Although adipose tissue and cells show considerable promise for clinical translation in the emerging field of regenerative medicine, they present a challenge to the regulatory community both nationally and internationally. This has been exacerbated by recent high-profile cases involving adverse events attributed to adipose cell-based therapies. This commentary evaluates the current status of adipose-derived therapeutics and considers regulatory approaches designed to maximize patient safety while advancing clinical translation in accordance with evidence based medical science.